Background

Antagonistic pleiotropy (AP) predicts that alleles favored early in life can be tolerated later if they impose costs after reproduction wanes [1]. In the colon, age‑related decline of DNA mismatch repair (MMR) and rise in microsatellite instability (MSI) exemplify this pattern [2,3]. Yet the molecular switch that silences MMR genes post‑reproductively remains unknown.

Hypothesis

We propose that the NAD⁺‑dependent deacetylase SIRT6 acts as an evolutionarily conserved sensor that actively represses MMR transcription when systemic nutrient signaling indicates a shift away from reproductive investment. In other words, SIRT6 mediates the AP trade‑off by linking metabolic state to epigenetic silencing of MMR, thereby facilitating field cancerization as a programmed, rather than stochastic, process.

Mechanistic Rationale

• SIRT6 deacetylates histone H3K9 and H3K56 at promoters of DNA repair genes, influencing their expression [4].
• NAD⁺ levels decline with age and are modulated by circadian and feeding cycles, which shift after menopause or reduced fecundity [5].
• Early‑life high mTORC1 activity, supportive of growth and reproduction, keeps NAD⁺ consumption low, permitting high SIRT6 activity elsewhere but low at MMR loci due to competing substrates.
• When reproductive signaling falls (e.g., reduced gonadotropins), NAD⁺ flux rises, SIRT6 activity increases at MMR promoters, leading to H3K9 deacetylation, chromatin compaction, and transcriptional silencing.
• This creates a permissive field for MSI, accelerating epigenetic age and CRC risk as a side‑effect of conserving resources for kin.

Testable Predictions

1. Prediction A: In post‑reproductive female mice, pharmacologic activation of SIRT6 (e.g., with MDL‑801) will maintain MMR protein levels (MLH1, MSH2) in colonic crypts compared with vehicle.
2. Prediction B: Mice with intestinal‑specific SIRT6 overexpression will show reduced MSI accumulation and lower incidence of age‑related colonic tumors, without altering litter size or early‑life growth metrics.
3. Prediction C: Conversely, conditional knockout of SIRT6 in intestinal stem cells of young, reproductively active mice will precipitate premature MMR silencing and MSI, mimicking the aged phenotype.

Experimental Approach

• Use C57BL/6J mice; monitor estrous cycles to define reproductive stage.
• Treat groups with SIRT6 activator, inhibitor, or vehicle for 6 months.
• Quantify MMR protein by immunohistochemistry and immunofluorescence in isolated crypts.
• Measure MSI using PCR‑based panels of microsatellite loci.
• Track tumor burden via colonoscopy and histopathology.
• Assess reproductive output (number of pups per litter, inter‑birth interval) to ensure early‑life fitness is unchanged.
• Parallel human validation: correlate colonic mucosal SIRT6 expression (from biopsy archives) with MSI status and epigenetic age acceleration in post‑menopausal women [6].

Potential Outcomes and Falsifiability

• If SIRT6 activation preserves MMR and reduces MSI without compromising early fecundity, the hypothesis gains support, indicating that the AP switch is druggable.
• If SIRT6 manipulation fails to affect MMR levels or MSI, or if it markedly alters litter size, the hypothesis is falsified, suggesting that MMR silencing occurs via a different, SIRT6‑independent mechanism.
• Demonstrating that SIRT6 loss in young mice accelerates MSI would further confirm its role as a deliberate, evolutionarily tuned brake on DNA repair.

By targeting the nutrient‑sensing node that couples reproductive state to MMR expression, this work reframes aging‑associated cancer risk not as inevitable damage but as a modifiable, evolutionarily programmed interface—offering a precise point where longevity medicine could negotiate with, rather than override, life‑history strategies.